Trials / Recruiting
RecruitingNCT06971744
Autophagy Maintenance (AUTOMAIN)
Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | 3 x 200 milligram tablets twice daily |
| DRUG | Nelfinavir | 2x 625 milligram tablets twice daily |
| DRUG | Bevacizumab | IV 15 milligram/kilogram every 3 weeks |
Timeline
- Start date
- 2025-12-18
- Primary completion
- 2028-06-18
- Completion
- 2029-06-18
- First posted
- 2025-05-14
- Last updated
- 2025-12-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06971744. Inclusion in this directory is not an endorsement.